The Drug Eluting Stents Center

Filter Your Results

 

News

 

A Roundtable Discussion on Results From the First Head-to-Head DES SFA Trial: IMPERIAL

With Michael R. Jaff, DO; Gary M. Ansel, MD, FACC; William A. Gray, MD; Steve Henao, MD, FACC, FACS; and Robert A. Lookstein, MD

January 2019—A multidisciplinary panel of PAD experts discuss the impact on patient care and the health care system and how these results may shift current treatment algorithms.

Discussing the IMPERIAL Data in Practice

With Yann Gouëffic, MD, PhD; and Andrew Holden, MBChB, FRANZCR, EBIR

January 2019—Two vascular experts share their reactions to hearing the results of the first head-to-head peripheral DES trial.

IMPERIAL 12-Month Full Cohort and Long Lesion Sub-Study Results

William A. Gray, MD; Additional commentary by Prof. Stefan Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA, FSIR

January 2019—Sustained drug-release in the SFA drives superior results.

Combining a Drug-Coated Balloon and a Bare-Metal Stent: The REsponse Adapted Combination Therapy (REACT) Strategy

Koen Deloose, MD, and B. Patrice Mwipatayi, MD, MMed, MClinEd, FCS, FRACS

September 2018—Allowing vessel response to guide appropriate treatment for SFA disease.

Assessing the Economic Impact of Peripheral Interventions

Yann Gouëffic, MD, PhD; and Valéry-Pierre Riche

September 2018—The difficulties in weighing cost-effectiveness in treatment algorithms remain.

The Importance of Vessel Preparation

Ralf Langhoff, MD

September 2018—Properly preparing lesions before use of drug-eluting technologies has become a crucial step of the treatment algorithm.

Bioresorbable Stent Technology for Femoropopliteal Disease Treatment: Where Do We Stand?

Sabine Steiner, MD; Andrej Schmidt, MD; and Dierk Scheinert, MD

September 2018—Appraising the current literature on bioresorbable technology use in the SFA, what can be learned from the coronary experience, and the future of bioresorbable stents in this anatomy.

Inert Technology: Actively Making a Difference in Drug-Eluting Stent Designs

November 2017—QualiMed’s sirolimus-eluting coronary stent is available under CE Mark only and is not approved in the United States. First-generation drug-eluting stents (DESs) deli…

 

advertisement

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.